Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper ...

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio than those receiving comparators such as placebo or another therapy ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects. Tirzepatide provided superior weight loss when compared with semaglutide ...

Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial ...

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

Tirzepatide treatment led to a 47% greater relative reduction in weight compared with semaglutide. Topline results were announced from a phase 3b clinical trial comparing tirzepatide with ...

Tirzepatide and semaglutide, both medications for obesity treatment, demonstrate similar safety and efficacy but tirzepatide resulted in greater levels of weight loss among patients compared with ...